USFDA issues warning to Dabur regarding data and quality issues
Dabur India has been issued a warning letter by the USFDA following an audit of its manufacturing plant in Silvassa, which uncovered suspected breaches in production standards. The health regulator highlighted issues regarding data accuracy, absent lab documentation, and insufficient quality management. The USFDA stated that the site's operations failed to comply with the CGMP guidelines mandated by American regulations.
by shortkt.com✓